What is TAMIFLU?

TAMIFLU is the only prescription antiviral pill indicated to prevent and treat type A and type B influenza in patients one year and older.

TAMIFLU was approved by the US Food and Drug Administration (FDA) in October 1999 for the treatment of uncomplicated acute illness due to influenza infection in adults.
TAMIFLU was granted FDA approval in November 2000 for the prevention of influenza in adults and adolescents 13 years and older.
TAMIFLU oral suspension was approved in December 2000 for use in the treatment of influenza types A and B in children one year and older.
TAMIFLU oral suspension can also be used in adult patients who cannot swallow a capsule.
In December 2005, the FDA approved the extension of the indication of TAMIFLU to include the prevention of influenza types A and B in children aged 1 through 12 years following close contact with an infected individual.

About 40 million people worldwide have been treated with TAMIFLU

TAMIFLU is approved in more than 80 countries, including the United States, Japan, Canada, the United Kingdom, South Africa and Australia, as well as many countries in Europe, the Far East and Latin America.

Advancing human progress through an economic, political and social system based on individual freedom, incentive, initiative, opportunity, and responsibility.